Medical Solutions Share Discussion Threads

[jotoha1] 21/1/2007 19:34

We are now entering a period of stagnation within the NHS, and all supplies especially the none essential ones are going to see a cut back in orders, that is a fact, have sources close to the decision makers that are already putting in plans for this next stage of new labour fiasco time,so do not expect anything exciting from this company for a very long time, unless of course they discover the secret to making easy money!

[lbo] 21/1/2007 16:58

Dirtysteve you asked what the above has to do with Medical solutions. Biomarkers will be one of the major growth areas for MLS

[paulo dicanio] 21/1/2007 12:47

This stock is Sadly like nearly all other "Penny Shares" the only real winners until most seem to go Bump are the highly paid Directors/Management who tend to nearly always Cream the companies as a rule ... And just for the record nearly always seem to be better at "Creaming" than Running the companies ! ... All "Imoho" of course ! ... And not saying this is the case with MLS ? ... Lol ... Although as previously stated in the past on a few occasions the "Mickey Mouse" NHS System/Government we sadly have in this country hasn't helped the MLS cause over the last 4/5yrs or so ?

[warranty] 19/1/2007 19:51

Come on peeps when did we ever see serious management buying in MLS even when they were threatening to do well prior to the NHS shafting them?? It's only mugs like us that keep this flag flying.

Is that morose enough spacey. lol

[spaceparallax] 19/1/2007 15:37

GDA,

Must confess to asking myself the same question.

Furthermore, why have we heard nothing about the acquisitions hinted at in the Dubai wrap-up?

[garey_de_angelis] 19/1/2007 15:17

nothing unless they get their fingers out.

Seems like the staff are just happy to draw salaries.

Why aren;t the directors buying if this is a cheap stock

[dirtysteve] 19/1/2007 12:32

What does that mean for MLS?

[spaceparallax] 19/1/2007 11:02

LBO,

Just what the hell do you think you're doing? This is a morose thread that will not tolerate upbeat news. LOL!

[lbo] 19/1/2007 10:54

$1 billion market slated for biomarkers in clinical trials - 17/01/2007

The growing use of biomarkers in clinical trials will push up worldwide revenues in this segment from $427 million in 2006 to more than $1 billion by 2010, a new report predicts.

Interest in biomarkers has soared due to their proven ability to accelerate pharmaceutical research and development, notes the report by Kalorama Information. This is at a time when pipeline productivity in the industry remains low, despite the significant progress made by key regulators such as the US Food and Drug Administration in streamlining pre-market review processes for new medicines.

In this respect, cutting the time and cost of Phase I and II trials by replacing clinical endpoints should be the most profitable application for biomarkers, Kalorama believes. The segment is already generating revenues of more than US$200 million, a figure that could swell by a factor of five over the next four years, suggests the report, Biomarkers: A Market Briefing.

Central to critical path initiative
The FDA has made biomarkers central to the Critical Path initiative it launched in March 2004 with the aim of modernising and streamlining medical product development. The agency sees a role for the next generation of predictive biomarkers in providing surrogate endpoints for efficacy; identifying safety problems at an early stage of clinical development; evaluating dose ranges; tracking disease progression; facilitating the emergence of novel and more effective clinical trial designs; and supplying new diagnostics that can measure responsiveness to targeted therapies.

The Critical Path Opportunities Report and List, which last March laid down a blueprint for priority research projects to be taken forward under the Initiative, includes Better Evaluation Tools as one of six broad topic areas in which opportunities exist to bridge the gap between biomedical discoveries and development. "FDA's outreach efforts uncovered a consensus that the two most important areas for improving medical product development are biomarker development and streamlining clinical trials," the agency pointed out.

Among the activities listed under this heading are developing a concept paper on biomarker qualification that will be the FDA's "first public statement on clarifying the nature and amount of evidence we will be looking for to support a variety of regulatory uses for biomarkers during medical product development".

Last year also saw the launch, in October, of The Biomarkers Consortium, a public-private research partnership supported by the Foundation for the National Institutes of Health, Inc (FNIH). This initiative, which already has a first set of projects approved for funding and implementation, involves a variety of stakeholders including the NIH, the FDA, industry, non-profit organisations and advocacy groups. By Peter Mansell

[lbo] 19/1/2007 10:49

$1 billion market slated for biomarkers in clinical trials - 17/01/2007

The growing use of biomarkers in clinical trials will push up worldwide revenues in this segment from $427 million in 2006 to more than $1 billion by 2010, a new report predicts.

Interest in biomarkers has soared due to their proven ability to accelerate pharmaceutical research and development, notes the report by Kalorama Information. This is at a time when pipeline productivity in the industry remains low, despite the significant progress made by key regulators such as the US Food and Drug Administration in streamlining pre-market review processes for new medicines.

In this respect, cutting the time and cost of Phase I and II trials by replacing clinical endpoints should be the most profitable application for biomarkers, Kalorama believes. The segment is already generating revenues of more than US$200 million, a figure that could swell by a factor of five over the next four years, suggests the report, Biomarkers: A Market Briefing.

Central to critical path initiative
The FDA has made biomarkers central to the Critical Path initiative it launched in March 2004 with the aim of modernising and streamlining medical product development. The agency sees a role for the next generation of predictive biomarkers in providing surrogate endpoints for efficacy; identifying safety problems at an early stage of clinical development; evaluating dose ranges; tracking disease progression; facilitating the emergence of novel and more effective clinical trial designs; and supplying new diagnostics that can measure responsiveness to targeted therapies.

The Critical Path Opportunities Report and List, which last March laid down a blueprint for priority research projects to be taken forward under the Initiative, includes Better Evaluation Tools as one of six broad topic areas in which opportunities exist to bridge the gap between biomedical discoveries and development. "FDA's outreach efforts uncovered a consensus that the two most important areas for improving medical product development are biomarker development and streamlining clinical trials," the agency pointed out.

Among the activities listed under this heading are developing a concept paper on biomarker qualification that will be the FDA's "first public statement on clarifying the nature and amount of evidence we will be looking for to support a variety of regulatory uses for biomarkers during medical product development".

Last year also saw the launch, in October, of The Biomarkers Consortium, a public-private research partnership supported by the Foundation for the National Institutes of Health, Inc (FNIH). This initiative, which already has a first set of projects approved for funding and implementation, involves a variety of stakeholders including the NIH, the FDA, industry, non-profit organisations and advocacy groups. By Peter Mansell

[stevi1111] 15/1/2007 22:02

Warranty - I'm sure it'll be back to the norm tomorrow.

Not even MLS falls in a straight line!

[warranty] 15/1/2007 21:43

Can't stand all this blue today am I really on MLS????

[warranty] 13/1/2007 13:43

You've been in this share long enough now to realise what a pile of poo MLS is. What else do you expect??

[spaceparallax] 12/1/2007 15:50

Even I'm feeling glum now - still can't figure it out.

[brutus2] 12/1/2007 15:36

must there big seller

[brutus2] 12/1/2007 15:34

500k / 700k @6.40 this morning

[cmillar] 12/1/2007 12:21

Couple of big trades reported on Plus markets

[paulo dicanio] 12/1/2007 12:16

Stevi1111 ... £1.25p for the Company of course ! Or do you think I have "Overvalued It " ? ... Lol ... It looks like MLS as gone back to it's "Secret Society" PR Days again ?

[dirtysteve] 12/1/2007 11:39

Why todays fall?

[stevi1111] 12/1/2007 10:56

I take it you guys mean £1.25 for the entire company - Not per share ?

[warranty] 12/1/2007 09:00

I'll take £1.25. LOL Louder!!

[paulo dicanio] 10/1/2007 19:19

£1.26p Me ... Lol